Richmond Pharmacology presents Improving Clinical Trial Design at the BAPU 4th 2-yearly Symposium 2012

Posted:
1
October 2012

Richmond Pharmacology presents �Improving Clinical Trial Design�at the BAPU 4th 2-yearly Symposium 2012

The Belgian Association of Phase 1 Units (BAPU) will host its 4th 2-yearly symposium this year in Antwerp, taking place 9th November 2012. The focus of this year�s meeting is modernising and innovation in early clinical drug development towards 2020.Founded in January 2005, BAPU represents the Belgian phase I clinical research units from both the pharmaceutical industry and academia. One of its primary objectives is to facilitate collaboration between Belgian phase I units as well as international phase I units and regulatory authorities.Invited on behalf of BAPU, Dr Ulrike Lorch�s presentation on Improving Clinical Trial Design will describe the benefit of adaptive design in First into Human and Early Phase Combination Studies, showing how its use, compared to conventional study designs, can lead to comprehensive time savings in early research programs.Click here to view full program and to registerWatch our latest presentation on Adaptive Study Design

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Contributing to our community in 2020

December 17, 2020
Richmond Pharmacology has a long-standing tradition of supporting local, national, and international charities and 2020 is no exception.
Read more

Richmond Pharmacology supports Cardior Pharmaceuticals with the pioneering trial of an oligonucleotide-based drug in heart failure patients

December 14, 2020
Richmond Pharmacology is delighted to welcome the positive Phase Ib results of Cardior Pharmaceuticals lead compound CDR132L for heart failure.
Read more

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more